Many people stop taking GLP-1 drugs like Ozempic within a year, but doing so often leads to weight regain. Here's what to know before stopping.

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock is a Buy.

LipoVive offers a safer, research-backed alternative, supporting metabolic balance, curbing cravings, and promoting steady ...

Thirty-nine percent of millennials and 35% of Gen Z say access to weight loss drugs would improve their job satisfaction or ...

When nurse practitioner Amy Rabon launched Sisterhood Sanctuary’s weight management program in 2019, 25 people signed up, ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

The first human-tested weight-loss drug that burns calories through creatine-based heat generation, without reducing appetite, has successfully completed its Phase I trial.

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

Some people are discovering that being thinner can sometimes mean looking older. Local cosmetic surgeons weigh-in with ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Whether the headlines cite Ozempic or obesity, Western media remains fixated on weight. But in East Asia, the conversation ...